Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
2013 June
  • Home
  • Archive for June, 2013

BIOSORTIA PHARMACEUTICALS INVITED TO PRESENT NATIONAL BUSINESS INNOVATION FORUM

  • June 26 2013

Dublin, OH (June 2013) – Dublin, Ohio-based Biosortia Pharmaceuticals has accepted the offer to present at the Innovation Forum in New York City on June 27th at the Yale Club. Biosortia, a premier, aquatic natural products company, is building a library of potent, active, and patented compounds with a primary focus on drug discovery in cancer,

Continue Reading

BIOSORTIA LAUNCHES INFECTIOUS DISEASE DRUG DISCOVERY TRIAL

  • June 11 2013

Dublin, OH (June 11, 2013) – Dr. Nancy Sawtell, a professor, and researcher at Cincinnati Children’s Hospital Medical Center, will be using technology developed by Biosortia Pharmaceuticals of Dublin, Ohio in collaboration to potentially discover new biologically active natural products for the treatment of infectious diseases. The drug discovery research is focused on the evaluation of

Continue Reading

RSS Industry News

  • Babies share microbiomes at nursery January 30 2026
  • Modeling diet-gut microbiome interactions and prebiotic responses in Thai adults January 28 2026
  • Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial January 28 2026
  • Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial January 28 2026
  • Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial January 28 2026
  • Large-scale capsid-mediated mobilisation of bacterial genomic DNA in the gut microbiome January 27 2026
  • Oral–gut bacterial transport drives chronic liver disease January 27 2026
  • Effector–host interactome map links type III secretion systems in healthy gut microbiomes to immune modulation January 26 2026
  • Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake January 24 2026
  • Tree bark microbiota in climate-active gas cycling January 23 2026
Quick Link
  • Products & Services
  • Blog
  • Contact
Recent Posts
  • AI, Microbiomes, & 8 Orders of Magnitude Improvement
  • Roche obesity drug shows 22.5% weight loss as it seeks to catch up with Lilly, Novo
  • The Billion Dollar Savings per Approved Drug
Sign up for our newsletter
Loading
Biosortia Microbiomics © 2026. All Rights Reserved.